Yeah, I'm not expecting much with sp. I see these giving others a bump but not usually cydy. The two big items for share price movement, financing (revenue, licensing etc) or combo news being closer to approval (as that moves the price model up with higher probability). The third being a wild card making leronlimab national news. Then mono pivotal approval might because of the massive revenue, the increase of probability with the trial approved moves the price model up and increases the chances BP will make a move significantly imo